Biosergen AB (BIOSGN.ST)
SEK 0.51
(-5.9%)
SEK 0.51
(-5.9%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -32.6 Million | -29.44 Million | -37.74 Million | -4.58 Million | -2.31 Million |
| Net Income | -27.03 Million | -34.12 Million | -34.07 Million | -6.22 Million | -5.42 Million |
| Depreciation & Amortization | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | -5.56 Million | 4.6 Million | -3.43 Million | 2.14 Million | 3.1 Million |
| Other non-cash items | 5.56 Million | 81 Thousand | -241 Thousand | -498 Thousand | 7.22 Million |
| Investing Cash Flow | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - |
| Financing Cash Flow | 5.14 Million | 37.11 Million | 70.59 Thousand | - | 5.8 Million |
| Debt repayment | - | - | - | - | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 5.14 Million | 37.11 Million | 58.82 Million | - | - |
| Other Financing Activities | 5144.00 | 37.11 Thousand | 70.59 Thousand | - | 5.8 Million |
| Accounts receivables | -681 Thousand | 3.37 Million | -3.72 Million | -2.74 Million | 59.11 Thousand |
| Accounts payables | -4.88 Million | 63 Thousand | 1.63 Million | 383 Thousand | -7.28 Million |
| Inventory | 4885.00 | - | 1000.00 | - | 1.00 |
| Other working capital | -4885.00 | 1.17 Million | -1.33 Million | 4.5 Million | 10.33 Million |
| Cash at beginning of period | 29.34 Million | 21.66 Million | 589 Thousand | 5.17 Million | 1.71 Million |
| Cash at end of period | 1.88 Million | 29.34 Million | 21.66 Million | 589 Thousand | 5.2 Million |
| Capital Expenditure | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | -27.45 Million | 7.67 Million | 21.07 Million | -4.58 Million | 3.48 Million |
| Free Cash Flow | -32.6 Million | -29.44 Million | -37.74 Million | -4.58 Million | -2.31 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -3.83 Million | -6.79 Million | -27.03 Million | -6.46 Million | -7.53 Million | -8.03 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 17.16 Million | -19.49 Million | -5.56 Million | 1.94 Million | -1.32 Million | 1.34 Million |
| Other non-cash items | 118 Thousand | -95 Thousand | 5.56 Million | -1.94 Million | 27 Thousand | 7000.00 |
| Investing Cash Flow | -4.4 Million | - | - | - | - | -4.52 Million |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -4.4 Million | - | - | - | - | -4.52 Million |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | 26.17 Million | 5.14 Million | 153 Thousand | 5.14 Million | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 26.17 Million | 5.14 Million | 153 Thousand | 5.14 Million | - |
| Other Financing Activities | - | 26.17 Thousand | 5144.00 | 153.00 | 5144.00 | - |
| Accounts receivables | 17.91 Million | -18.5 Million | -681 Thousand | -53 Thousand | 2.18 Million | 1.33 Million |
| Accounts payables | 1.21 Million | -996 Thousand | -4.88 Million | 1.99 Million | -3.51 Million | 7000.00 |
| Inventory | - | - | 4885.00 | -1998.00 | 3511.00 | -7.00 |
| Other working capital | -575.00 | -996.00 | -4885.00 | 1998.00 | -3511.00 | 7.00 |
| Cash at beginning of period | 1.16 Million | 1.88 Million | 29.34 Million | 6.4 Million | 10.1 Million | 16.78 Million |
| Cash at end of period | 10.2 Million | 1.66 Million | 1.88 Million | 1.88 Million | 6.4 Million | 10.1 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 9.03 Million | -214 Thousand | -27.45 Million | -4.52 Million | -3.69 Million | -6.68 Million |
| Free Cash Flow | 13.44 Million | -26.38 Million | -32.6 Million | -4.52 Million | -8.83 Million | -6.68 Million |
3073
ANZLY
EBO
600845
NIVF
WWL